Abstract
Drug resistance represents a serious barrier to the successful treatment of hematological malignancies. In leukemias, resistance mechanisms that involve membrane-resident proteins belonging to the ABC (ATP-binding cassette) transporter protein family are of particular interest, wherein enhanced expression is often associated with poor prognosis and frequent in relapsed or refractory disease. These proteins reduce the intracellular concentration of antitumor agents, greatly diminishing clinical efficacy. Research in this area has been directed at the design of agents, “pump antagonists”, to overcome the effluxing capacity of drug transporters; however, this direction has had limited clinical success. An allied function of ABC transporters like P-glycoprotein (P-gp) is glycolipid trafficking, an area that has not been explored from a therapeutic standpoint. In this capacity, it turns out that glycolipid synthesis can be attenuated by pump antagonists; this is perhaps an adventitious property of P-gp. Recent research in the area of lipid metabolism, specifically ceramide and glycolipids, has provided insight into the function of glycosphingolipids in multidrug resistance and in the action of chemotherapy. This review is intended to bring together those aspects of glycosphingolipid metabolism that might be leveraged to enhance the therapeutic performance of ceramide and to discuss how ABC transporters like P-gp might be targeted to potentiate and magnify ceramide-driven proapoptotic cascades.
Keywords: Ceramide, drug resistance, glucosylceramide, glucosylceramide synthase, glycosphingolipids, leukemia, P-glycoprotein, sphingolipids, GCS, SMS, TNF, FAS
Anti-Cancer Agents in Medicinal Chemistry
Title: Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Volume: 11 Issue: 9
Author(s): Valerie Gouaze-Andersson and Myles C. Cabot
Affiliation:
Keywords: Ceramide, drug resistance, glucosylceramide, glucosylceramide synthase, glycosphingolipids, leukemia, P-glycoprotein, sphingolipids, GCS, SMS, TNF, FAS
Abstract: Drug resistance represents a serious barrier to the successful treatment of hematological malignancies. In leukemias, resistance mechanisms that involve membrane-resident proteins belonging to the ABC (ATP-binding cassette) transporter protein family are of particular interest, wherein enhanced expression is often associated with poor prognosis and frequent in relapsed or refractory disease. These proteins reduce the intracellular concentration of antitumor agents, greatly diminishing clinical efficacy. Research in this area has been directed at the design of agents, “pump antagonists”, to overcome the effluxing capacity of drug transporters; however, this direction has had limited clinical success. An allied function of ABC transporters like P-glycoprotein (P-gp) is glycolipid trafficking, an area that has not been explored from a therapeutic standpoint. In this capacity, it turns out that glycolipid synthesis can be attenuated by pump antagonists; this is perhaps an adventitious property of P-gp. Recent research in the area of lipid metabolism, specifically ceramide and glycolipids, has provided insight into the function of glycosphingolipids in multidrug resistance and in the action of chemotherapy. This review is intended to bring together those aspects of glycosphingolipid metabolism that might be leveraged to enhance the therapeutic performance of ceramide and to discuss how ABC transporters like P-gp might be targeted to potentiate and magnify ceramide-driven proapoptotic cascades.
Export Options
About this article
Cite this article as:
Gouaze-Andersson Valerie and C. Cabot Myles, Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/187152011797655069
DOI https://dx.doi.org/10.2174/187152011797655069 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design Biological Basis of Novel Therapies for Myelodysplastic Syndrome
Current Cancer Therapy Reviews Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cell-based Therapy for Ocular Disorders: A Promising Frontier
Current Stem Cell Research & Therapy A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic Malignancies
Current Pharmaceutical Design Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Current Pharmaceutical Design Gene therapy for Multiple Myeloma
Current Gene Therapy Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Current Status of Epigenetics and Anticancer Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species
Current Pharmaceutical Design Regulatory T Cell Counts and Development of Malignancy in Patients with HIV Infection
Current HIV Research Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery